217 related articles for article (PubMed ID: 14737744)
1. All-cause mortality in diabetic patients treated with combinations of sulfonylureas and biguanides.
Mannucci E; Monami M; Masotti G; Marchionni N
Diabetes Metab Res Rev; 2004; 20(1):44-7. PubMed ID: 14737744
[TBL] [Abstract][Full Text] [Related]
2. Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-related mortality.
Monami M; Balzi D; Lamanna C; Barchielli A; Masotti G; Buiatti E; Marchionni N; Mannucci E
Diabetes Metab Res Rev; 2007 Sep; 23(6):479-84. PubMed ID: 17385195
[TBL] [Abstract][Full Text] [Related]
3. Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study.
Simpson SH; Majumdar SR; Tsuyuki RT; Eurich DT; Johnson JA
CMAJ; 2006 Jan; 174(2):169-74. PubMed ID: 16415461
[TBL] [Abstract][Full Text] [Related]
4. The risk of overall mortality in patients with Type 2 diabetes receiving different combinations of sulfonylureas and metformin: a retrospective analysis.
Pantalone KM; Kattan MW; Yu C; Wells BJ; Arrigain S; Nutter B; Jain A; Atreja A; Zimmerman RS
Diabet Med; 2012 Aug; 29(8):1029-35. PubMed ID: 22248043
[TBL] [Abstract][Full Text] [Related]
5. Influence of an antidiabetic treatment with sulfonylurea drugs on long-term survival after acute myocardial infarction in patients with type 2 diabetes. The LAngendreer Myocardial infarction and Blood glucose in Diabetic patients Assessment (LAMBDA).
Meier JJ; Deifuss S; Klamann A; Schmiegel W; Nauck MA;
Exp Clin Endocrinol Diabetes; 2003 Sep; 111(6):344-50. PubMed ID: 14520601
[TBL] [Abstract][Full Text] [Related]
6. Incidence of severe sideeffects during therapy with sulfonylureas and biguanides.
Berger W
Horm Metab Res Suppl; 1985; 15():111-5. PubMed ID: 3865878
[TBL] [Abstract][Full Text] [Related]
7. The effect of pioglitazone as add-on therapy to metformin or sulphonylurea compared to a fixed-dose combination of metformin and glibenclamide on diabetic dyslipidaemia.
Comaschi M; Corsi A; Di Pietro C; Bellatreccia A; Mariz S;
Nutr Metab Cardiovasc Dis; 2008 Jun; 18(5):373-9. PubMed ID: 17919894
[TBL] [Abstract][Full Text] [Related]
8. Common variation in the NOS1AP gene is associated with reduced glucose-lowering effect and with increased mortality in users of sulfonylurea.
Becker ML; Aarnoudse AJ; Newton-Cheh C; Hofman A; Witteman JC; Uitterlinden AG; Visser LE; Stricker BH
Pharmacogenet Genomics; 2008 Jul; 18(7):591-7. PubMed ID: 18551039
[TBL] [Abstract][Full Text] [Related]
9. Variability of body weight, pulse pressure and glycaemia strongly predict total mortality in elderly type 2 diabetic patients. The Verona Diabetes Study.
Zoppini G; Verlato G; Targher G; Bonora E; Trombetta M; Muggeo M
Diabetes Metab Res Rev; 2008; 24(8):624-8. PubMed ID: 18802932
[TBL] [Abstract][Full Text] [Related]
10. Three-year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin.
Monami M; Luzzi C; Lamanna C; Chiasserini V; Addante F; Desideri CM; Masotti G; Marchionni N; Mannucci E
Diabetes Metab Res Rev; 2006; 22(6):477-82. PubMed ID: 16634115
[TBL] [Abstract][Full Text] [Related]
11. [Behavior of lactate and pyruvate in diabetics during ambulatory treatment with biguanides or with a combination of biguanides and sulfonylureas. II].
Lunetta M; Presti C; Mughini MT; Mughini L
Clin Ter; 1980 Jun; 93(6):657-72. PubMed ID: 6775864
[No Abstract] [Full Text] [Related]
12. Cancer mortality reduction and metformin: a retrospective cohort study in type 2 diabetic patients.
Bo S; Ciccone G; Rosato R; Villois P; Appendino G; Ghigo E; Grassi G
Diabetes Obes Metab; 2012 Jan; 14(1):23-9. PubMed ID: 21812892
[TBL] [Abstract][Full Text] [Related]
13. Triglyceride predicts cardiovascular mortality and its relationship with glycaemia and obesity in Chinese type 2 diabetic patients.
Chan WB; Tong PC; Chow CC; So WY; Ng MC; Ma RC; Osaki R; Cockram CS; Chan JC
Diabetes Metab Res Rev; 2005; 21(2):183-8. PubMed ID: 15386811
[TBL] [Abstract][Full Text] [Related]
14. Cause-specific mortality in insulin-treated diabetic patients: a 20-year follow-up.
Dawson SI; Willis J; Florkowski CM; Scott RS
Diabetes Res Clin Pract; 2008 Apr; 80(1):16-23. PubMed ID: 18329124
[TBL] [Abstract][Full Text] [Related]
15. [Circadian profiles of lactic and pyruvic acid in diabetic patients treated with biguanides and sulfonylureas].
Cheli V; Buzzo P; Melga P; Accoto S; Prando R
Clin Ter; 1986 Aug; 118(4):269-75. PubMed ID: 3757467
[No Abstract] [Full Text] [Related]
16. Oral hypoglycemics: increased postoperative mortality in coronary risk patients.
Jeger RV; Seeberger MD; Keller U; Pfisterer ME; Filipovic M
Cardiology; 2007; 107(4):296-301. PubMed ID: 17264509
[TBL] [Abstract][Full Text] [Related]
17. Mortality in type 2 diabetic subjects prescribed metformin and sulphonylurea drugs in combination: cohort study.
Gulliford M; Latinovic R
Diabetes Metab Res Rev; 2004; 20(3):239-45. PubMed ID: 15133756
[TBL] [Abstract][Full Text] [Related]
18. Association of diet alone, insulin, sulfonylureas, metformin, and thiazolidinediones with the severity of coronary artery disease in patients with diabetes mellitus.
Ravipati G; Aronow WS; Ahn C; Sujata K; Saulle LN; Channamsetty V; Weiss MB
Am J Ther; 2006; 13(5):400-3. PubMed ID: 16988534
[TBL] [Abstract][Full Text] [Related]
19. IDF and ATP-III definitions of metabolic syndrome in the prediction of all-cause mortality in type 2 diabetic patients.
Monami M; Marchionni N; Masotti G; Mannucci E
Diabetes Obes Metab; 2007 May; 9(3):350-3. PubMed ID: 17391162
[TBL] [Abstract][Full Text] [Related]
20. 'Warm-up' phenomenon in diabetic patients with stable angina treated with diet or sulfonylureas.
Bilinska M; Potocka J; Korzeniowska-Kubacka I; Piotrowicz R
Coron Artery Dis; 2007 Sep; 18(6):455-62. PubMed ID: 17700217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
